NCT04590248CompletedPhase 2
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 109
- Locations
- 1
- Primary Endpoint
- Objective Response Rate (ORR)
Study Overview
Brief Summary
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Detailed Description
This Phase 2b, open-label, single-arm, multi-center study will assess the efficacy and safety of adavosertib in eligible subjects with histologically confirmed recurrent or persistent USC, evidence of measurable disease as per Response Evaluation Criteria in Solid Tumors.(RECIST) v1.1, and who have received at least 1 prior platinum-based chemotherapy regimen for the management of USC. Subjects with carcinosarcomas are not eligible.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 130 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects must be aged ≥ 18 years of age inclusive, at the time of signing the informed consent.
- •Histologically confirmed recurrent or persistent USC. Subjects with carcinosarcomas are not eligible.
- •Evidence of measurable disease as per RECIST v1.
- •At least 1 prior platinum-based chemotherapy regimen for the management of USC. Prior receipt of immune checkpoint inhibitors, vascular endothelial growth factor (VEGF) inhibitors and human epidermal growth factor receptor 2 (HER2) targeted therapy is allowed. There is no restriction on the number of prior lines of systemic therapy.
- •Eastern Cooperative Oncology Group performance (ECOG) status 0-
- •Life expectancy ≥ 12 weeks.
- •Subjects must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
- •Consent to submit and provide a mandatory Formalin-fixed paraffin-embedded tumor sample for central testing.
- •Female subjects who are not of childbearing potential and women of childbearing potential who agree to use adequate contraceptive measures.
Exclusion Criteria
- •Any underlying medical condition and uncontrolled intercurrent illness that would impair the ability of the subject to receive study treatment, as judged by the investigator.
- •With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment.
- •Unable to swallow oral medications.
- •Spinal cord compression or metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
- •Subjects with current signs or symptoms of bowel obstruction, including sub-occlusive disease, related to underlying disease.
- •Any of the following cardiac diseases currently or within the last 6 months:
- •Unstable angina pectoris
- •Acute myocardial infarction
- •Congestive heart failure
- •Conduction abnormality not controlled with pacemaker or medication
- •Significant ventricular or supraventricular arrhythmias
- •History of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected.
- •a) Resting corrected QTc interval using the Fridericia formula (QTcF) > 480 msec, or b) congenital long QT syndrome.
- •Immunocompromised subjects.
- •Subjects with known active hepatitis (ie, hepatitis B or C).
- •Prior treatment with any of the following:
- •Cell cycle checkpoint inhibitor.
- •Anticancer treatment drug ≤ 21 days (≤ 6 weeks for nitrosoureas or mitomycin C) or use of an investigational product within 5 half-lives prior to the first dose of adavosertib. For Programmed cell death-1 receptor (PD-1) /Programmed death-ligand 1 (PD-L1) inhibitors, a minimum of 28 days since last dose is required.
- •Prescription or non-prescription drugs known as moderate to strong inhibitors / inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment.
- •Herbal medications 7 days prior to first dose of study treatment.
- •Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation within 4 weeks prior to the first dose of study intervention.
- •Major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, prior to beginning study.
- •Subjects with a known hypersensitivity or contraindication to adavosertib or any of the excipients of the product.
- •Currently pregnant or breast-feeding.
Arms & Interventions
Adavosertib
Experimental
Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Intervention: Adavosertib (Drug)
Outcomes
Primary Outcomes
Objective Response Rate (ORR)
Time Frame: up to 75 weeks
Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for target lesions (TLs) and assessed by computed tomography (CT) or magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions; Partial response (PR), \>=30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Secondary Outcomes
- Depth of Response(Up to 75 weeks)
- Progression Free Survival (PFS)(Up to 75 weeks)
- Overall Survival (OS)(Up to 75 weeks)
- Lowest Concentration (Ctrough) of Adavosertib(Cycle 1, Day 5 and Cycle 2, Day 5 (pre-dose) (each cycle is 21 days))
- Disease Control Rate (DCR)(Up to 75 weeks)
- Progression Free Survival Rate at 6 Months (PFS6)(Up to 6 months)
- Duration of Response (DoR)(up to 75 weeks)
- Maximum Concentration (Cmax) of Adavosertib(Cycle 1, Day 5 and Cycle 2, Day 5 (2 hours post-dose) (each cycle is 21 days))
- Number of Participants With Treatment Emergent Adverse Events (AEs)(From baseline to post-treatment follow-up (30 days after last dose), approximately up to 114 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Locally Advanced Merkel Cell CarcinomaMetastatic Merkel Cell CarcinomaRefractory Merkel Cell CarcinomaUnresectable Merkel Cell CarcinomaNCT05947500National Cancer Institute (NCI)50
Completed
Phase 2
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)Ovarian CancerNCT06433219EMD Serono Research & Development Institute, Inc.63
Withdrawn
Not Applicable
Phase II trial of Vistusertib(AZD2014) single agent in TSC1or 2 null or TSC 1/2 mutation solid cancer patients refractory to standard chemotherapyNeoplasmsKCT0003961Samsung Medical Center27
Withdrawn
Phase 2
Adavosertib and Gemcitabine in Advanced PancreaticPancreatic CancerNCT05212025James Cleary, MD, PhD
Active, not recruiting
Phase 2
Phase 2 Study of Alisertib Therapy for Rhabdoid TumorsMalignant Rhabdoid TumorAtypical Teratoid Rhabdoid TumorNCT02114229St. Jude Children's Research Hospital125